Skip to main content
OpenTrials
Completed

NCT Number: NCT04605991

A Study of Mealtime Insulin LY900014 in Participants With Type 2 Diabetes Using Continuous Glucose Monitoring (PRONTO-Time in Range)

This study is being done to evaluate glycemic control in participants with type 2 diabetes who are taking mealtime insulin LY900014 in combination with long-acting insulin glargine. Participants will use continuous glucose monitoring (CGM) (Freestyle Libre 14-day system) during the study.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Type 2 Diabetes Diabetes Mellitus Diabetes Mellitus, Type 2 Endocrine System Diseases Glucose Metabolism Disorders Metabolic Diseases Nutritional and Metabolic Diseases

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 3

Primary location

Manati Center for Clinical Research Inc, Manati, PR, Puerto Rico

Loading trial locations.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Participants diagnosed (clinically) with type 2 diabetes mellitus (T2D) for at least 1 year prior to screening.
  • Have been treated with basal-bolus multiple daily injection (MDI) therapy for at least 90 days prior to screening including:
  • Basal insulin glargine U-100, in combination with bolus insulin analog (insulin lispro, insulin aspart, or insulin glulisine) with meals.
  • Participant must have been treated with the same type of allowed bolus insulin analog for at least 30 days prior to screening.
  • Participants may be treated with up to 3 of the following oral antihyperglycemic medications (OAMs) for T2D in accordance with local regulations:
  • Metformin
  • Dipeptidyl peptidase-4 (DPP-4) inhibitor
  • sodium glucose cotransporter 2 (SGLT2) inhibitor
  • oral glucagon-like peptide 1 (GLP-1) agonist
  • Doses of OAMs are required to have been stable for at least 90 days prior to screening.
  • Participants may be treated with injectable GLP-1 receptor agonist for T2D in accordance with local regulations. The GLP-1 receptor agonist dose is required to have been stable for at least 90 days prior to screening.
  • Have an HbA1c value ≥7.5% and ≤10% according to the central laboratory at screening.

Exclusion criteria

  • Have been diagnosed at any time with type 1 diabetes mellitus or latent autoimmune diabetes in adults.
  • Have had any episode of severe hypoglycemia (defined as requiring assistance due to neurologically disabling hypoglycemia) within 6 months prior to screening.
  • Have had any episode of hyperglycemic hyperosmolar state or diabetic ketoacidosis within 6 months prior to screening.
  • Have hypoglycemia unawareness as judged by the investigator.

Treatment and study plan

LY900014

Drug

Administered SC

insulin glargine

Drug

Administered SC

Primary outcomes

  1. Change From Baseline in Percentage of Time With Continuous Glucose Monitoring (CGM) Sensor Glucose Values Between 70-180 Milligrams/Deciliter (mg/dL) (3.9-10.0 Millimoles/Liter [mmol/L]) (Both Inclusive) During Daytime Period at Week 12

    Time frame: Baseline, Week 12

    Least Squares (LS) mean was determined by mixed-model repeated measures (MMRM) model with Baseline + Time as variables.

Secondary outcomes

  1. Change From Baseline in Hemoglobin A1c (HbA1c) at Week 12

    Time frame: Baseline, Week 12

    HbA1c is the glycosylated fraction of hemoglobin A. It is measured to identify average plasma glucose concentration over prolonged periods of time. LS mean was determined by MMRM model with Baseline + Time as variables.

  2. Change From Baseline in Percentage of Time With CGM Sensor Glucose Values Between 70-180 mg/dL (3.9-10.0 mmol/L) (Both Inclusive) During the 24-hour Period at Week 12

    Time frame: Baseline, Week 12

    LS mean was determined by MMRM model with Baseline + Time as variables.

  3. Change From Baseline in Percentage of Time With CGM Sensor Glucose Values <54 mg/dL (<3.0 mmol/L) During Daytime and 24-hour Periods at Week 12

    Time frame: Baseline, Week 12

    LS mean was determined by MMRM model with Baseline + Time as variables.

  4. Change From Baseline in Percentage of Time With CGM Sensor Glucose Values >180 mg/dL (>10.0 mmol/L) During Daytime and 24-hour Period at Week 12

    Time frame: Baseline, Week 12

    LS mean was determined by MMRM model with Baseline + Time as variables.

  5. Change From Baseline in Percentage of Time With CGM Sensor Glucose Value >250 mg/dL (>13.9 mmol/L) During Daytime and 24-hour Period at Week 12

    Time frame: Baseline, Week 12

    LS mean was determined by MMRM model with Baseline + Time as variables.

  6. Change From Baseline in Postprandial Incremental Area Under the Glucose Curve (iAUC) 0-1 Hour at Week 12

    Time frame: Baseline, Week 12

    iAUC reflects the metabolic control and is calculated using the standard trapezoidal rule from Glucose measures taken every 15 minutes from 0 to 1 hour after meal using CGM sensor (i.e., 0, 15, 30, 45, 60 minutes after meal). LS mean was determined by ANCOVA (analysis of covariance) with Baseline as covariate.

  7. Change From Baseline in Postprandial Incremental Area Under the Glucose Curve (iAUC) 0-2 Hour at Week 12

    Time frame: Baseline, Week 12

    iAUC reflects the metabolic control and is calculated using the standard trapezoidal rule from glucose measures taken every 15 minutes from 0 to 2 hours after meal using CGM sensor (i.e., 0, 15, 30, 45, 60, 75, 90, 105, 120 minutes after meal). LS mean was determined by ANCOVA (analysis of covariance) with Baseline as covariate.

  8. Percentage of Participants With HbA1c <7% and ≤6.5%

    Time frame: Week 12

    HbA1c is the glycosylated fraction of hemoglobin A. It is measured to identify average plasma glucose concentration over prolonged periods of time.

  9. Change From Baseline in Daily Insulin Dose at Week 12

    Time frame: Baseline, Week 12

    LS mean was determined by MMRM model with Baseline + Time as variables.

  10. Change From Baseline in Bolus/Total Insulin Dose Percentage at Week 12

    Time frame: Baseline, Week 12

    LS mean was determined by MMRM model with Baseline + Time as variables.

  11. Change From Baseline in Insulin Treatment Satisfaction Questionnaire (ITSQ) - Glycemic Control Domain Score at Week 12

    Time frame: Baseline, Week 12

    The ITSQ is a 22-item questionnaire that assesses treatment satisfaction for subjects taking insulin under 5 domains: Inconvenience of Regimen [IR - 5 items], Lifestyle Flexibility [LF - 3 items], Glycemic Control [GC - 3 items], Hypoglycemic Control [HC - 5 items], Insulin Delivery Device [IDD - 6 items]. Each Item is measured on a 7-point scale, with scores ranging for IR from 5 to 35, LF from 3 to 21, GC from 3 to 21, HC from 5 to 35, IDD from 6 to 42. Lower scores reflect better outcomes. Data presented are for Glycemic Control Domain Scores transformed on a 0-100 scale, where transformed domain score = 100×[(7-raw domain score)/6]. Higher scores indicate better glycemic control. Least squares (LS) mean estimated from analysis of covariance (ANCOVA) model that included baseline score as a covariate.

Sponsors and collaborators

Lead sponsor

Eli Lilly and Company

Industry

Registry information

Official study title

A Study of LY900014 in Participants With Type 2 Diabetes Using Continuous Glucose Monitoring

Important dates

Study start
2020
Primary completion
2022
Study completion
2022
First posted
Oct 28, 2020
Registry last updated
Mar 3, 2023

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.